INTRODUCTION: Somatic KRAS mutations have been identified in the majority of brain arteriovenous malformations (AVM) specimens. The aim of our study was to evaluate the prevalence of Kirsten rat sarcoma (KRAS)/murine sarcoma viral oncogene homolog B1 (BRAF) mutations in brain AVM. METHODS: A systematic literature review was performed in November 2019. We reviewed MEDLINE/PubMed, Cochrane Library, and ClinicalTrials.gov for citation or ongoing trials from January 2010 to March 2020. RESULTS: 6 studies were identified as meeting the inclusion criteria of this review. The total frequency of KRAS mutations in 1726 patients with AVM was 55%. The prevalence of BRAF mutation was 7.5%. The prevalence of AVMs with grade 2 was the most (39%). Frontal and parietal lobes were the commonest sites of AVMs (21%). the most prevalent presentation of patients with AVM was hemorrhage (62%). CONCLUSION: Our findings support a high prevalence of somatic activating mutations in KRAS and less commonly, BRAF in the overwhelming majority of brain AVMs. Practically and importantly, this pathway homogeneity in CNS arteriovenous malformations also supports the development of targeted therapies with RAS/RAF pathway inhibitors. However, more studies are needed to confirm this hypothesis.
INTRODUCTION: Somatic KRAS mutations have been identified in the majority of brain arteriovenous malformations (AVM) specimens. The aim of our study was to evaluate the prevalence of Kirsten rat sarcoma (KRAS)/murine sarcoma viral oncogene homolog B1 (BRAF) mutations in brain AVM. METHODS: A systematic literature review was performed in November 2019. We reviewed MEDLINE/PubMed, Cochrane Library, and ClinicalTrials.gov for citation or ongoing trials from January 2010 to March 2020. RESULTS: 6 studies were identified as meeting the inclusion criteria of this review. The total frequency of KRAS mutations in 1726 patients with AVM was 55%. The prevalence of BRAF mutation was 7.5%. The prevalence of AVMs with grade 2 was the most (39%). Frontal and parietal lobes were the commonest sites of AVMs (21%). the most prevalent presentation of patients with AVM was hemorrhage (62%). CONCLUSION: Our findings support a high prevalence of somatic activating mutations in KRAS and less commonly, BRAF in the overwhelming majority of brain AVMs. Practically and importantly, this pathway homogeneity in CNS arteriovenous malformations also supports the development of targeted therapies with RAS/RAF pathway inhibitors. However, more studies are needed to confirm this hypothesis.
Authors: Ondrej Fiala; Tomas Buchler; Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Marie Bartouskova; Vaclav Liska; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek Journal: Tumour Biol Date: 2015-12-10
Authors: D W Johnson; J N Berg; M A Baldwin; C J Gallione; I Marondel; S J Yoon; T T Stenzel; M Speer; M A Pericak-Vance; A Diamond; A E Guttmacher; C E Jackson; L Attisano; R Kucherlapati; M E Porteous; D A Marchuk Journal: Nat Genet Date: 1996-06 Impact factor: 38.330
Authors: K A McAllister; K M Grogg; D W Johnson; C J Gallione; M A Baldwin; C E Jackson; E A Helmbold; D S Markel; W C McKinnon; J Murrell Journal: Nat Genet Date: 1994-12 Impact factor: 38.330
Authors: Iiro Eerola; Laurence M Boon; John B Mulliken; Patricia E Burrows; Anne Dompmartin; Shoji Watanabe; Romain Vanwijck; Miikka Vikkula Journal: Am J Hum Genet Date: 2003-11-24 Impact factor: 11.025
Authors: Carol J Gallione; Gabriela M Repetto; Eric Legius; Anil K Rustgi; Susan L Schelley; Sabine Tejpar; Grant Mitchell; Eric Drouin; Cornelius J J Westermann; Douglas A Marchuk Journal: Lancet Date: 2004-03-13 Impact factor: 79.321
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329